Phase 2 Randomized Trial of Conventional Versus Hypofractionated Post-Mastectomy Proton Radiotherapy
Robert W. Mutter, M.D.

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

• Discuss the rationale for proton therapy for breast cancer
• Describe outcomes of a clinical trial comparing 15 versus 25 fraction proton post-mastectomy radiotharapy

Population-based Estimates of Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2
Siddhartha Yadav, M.B.B.S., M.D., F.A.C.P.

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

• Define the risk of contralateral breast cancer in carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2
• Describe the modifying effects of age at diagnosis of first breast cancer, race/ethnicity and menopausal status on the risk of contralateral breast cancer in germline mutation carriers

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

Presenters:
Robert W. Mutter, M.D.
Siddhartha Yadav, M.B.B.S., M.D., F.A.C.P.

Support location:
Minnesota